Alan J. Tuchman - 31 Dec 2025 Form 5 Insider Report for TAO Synergies Inc. (TAOX)

Reporting relationship: Chief Medical Officer, Director
Issuer ticker: TAOX
Reported as of: 31 Dec 2025
Net transaction value: $0
SEC form: 5
Accepted by SEC: 05 Feb 2026, 17:14:08 UTC
Prior SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Weinstein, Attorney-in-fact

Key filing fact

Alan J. Tuchman filed Form 5 for TAO Synergies Inc. (TAOX) on 05 Feb 2026.

Key facts

This page summarizes Alan J. Tuchman's Form 5 filing for TAO Synergies Inc. (TAOX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2026, 17:14.

Change

Previous filing in this sequence was filed on 02 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reporting Owners (1)

CIK 0001417631 Primary reporting owner

TUCHMAN ALAN J

Relationship: Chief Medical Officer, Director
Address: C/O TAO SYNERGIES INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Signature: /s/ Robert Weinstein, Attorney-in-fact
Signature date: 05 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TAOX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +2,000
Change %
Price: $0.000000
Shares after: 2,000
Date: 06 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000
Exercise price: $10.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Alan J. Tuchman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

The option grant was approved by a committee of TAO Synergies Inc.'s (the "Issuer") board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Company's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Company received shareholder approval of the amendment to the Plan on August 6, 2025.